Our website looks best when viewed through a more modern browser such as Google Chrome, Mozilla Firefox, Apple Safari or Microsoft Edge.

If you would like to download one of these browsers, click here.

Modern Slavery Statement

For the financial year ended 31 December 2018

1.  Chief Executive Officer’s Statement

Morningside Pharmaceuticals Limited
(MPL) is committed to preventing acts of modern slavery and human trafficking
from occurring within its business and supply chains, including subcontractors
and partners. As part of the pharmaceutical industry, MPL recognises that it
has a responsibility to take a robust approach to slavery and human trafficking
in order to tackle hidden labour exploitation proactively. 

2.  Morningside Pharmaceuticals Limited

MPL is a manufacturer, wholesaler and exporter of branded
and generic medicines and healthcare products worldwide. It is our vision to
make quality healthcare an affordable and accessible reality throughout the
world.  MPL acknowledges its responsibility to the Modern Slavery Act 2015
and will ensure transparency within the organisation and with the supply and
sale of goods and services to the organisation. MPL’s holding company is Remedi
Medical Holdings Ltd and all trading activities are carried out through MPL.

3. Our Supply Chains and our Due Diligence

MPL purchases and manufactures licensed medicines and
Healthcare products from the European Union (EU) and other non-EU countries. We
believe that the area with the greatest risk of these practices is within our
Contract Manufacturing Organisations (CMOs) outside the EU.

Since January 2018, following a risk assessment on
Anti-Slavery and Human Trafficking, we have requested that our CMOs with the
‘Greatest Risk’ complete our Anti-Modern Slavery and Bribery Ethical
Self-Assessment Questionnaire bi-annually as part of the due diligence process.
They are requested to provide information about their policies on human rights,
anti-bribery and workplace conditions. We reviewed this Questionnaire in
late 2018 to produce a more focussed document with the aim of encouraging prompt
completion by our CMO’s.

We carried out a further risk assessment of our supply
chain in December 2018 using the Global Slavery Index Data Map to identify low,
medium and high-risk categories. As a result of our risk assessment, all
CMOs and non-EU healthcare product suppliers will be sent a Supplier Code of
Conduct form to complete and to confirm their compliance with laws and
regulations in relation to the provision of their services and the rights and
welfare of their workers and the standards MPL expect of them.  For
greater risk CMO’s/suppliers or those identified as a result of any concerns we
will issue a self-assessment questionnaire and track completion. 

4.  Morningside Pharmaceuticals Limited’s
Responsibilities and Policies

The CEO, Directors and Management take responsibility for
implementing the measures set out in this statement and its objectives, and
shall provide adequate resources (training, etc.) and investment to ensure that
Modern Slavery and Human Trafficking is not taking place within the
organisation and its supply chains. We have in place an Anti-Slavery and Human
Trafficking Procedure that sets out the process to be followed in relation to

In addition, our Anti-Slavery and Human Trafficking
Policy reflects our commitment to acting ethically and with integrity in all
our business relationships and to implementing and enforcing effective systems
and monitoring to ensure slavery and human trafficking is not taking place
anywhere in our supply chains. We also have systems in place to enable
our workforce to raise concerns through our Grievance Policy, Whistleblowing
Policy and our Anti-Corruption and Bribery Procedure.  We ensure
compliance with UK legislation in relation to employment of staff and we have
zero tolerance to slavery and human trafficking.

5.  Education and Training

The Human Resources Department will take responsibility
for ensuring that all MPL employees are aware of MPL’s statement of compliance
with the Modern Slavery Act 2015 and its on-going commitments; and must also
ensure that this statement is displayed on MPL’s website and an overview of our
Anti-Slavery and Human Trafficking Policy is included in the Employee Handbook.
MPL will provide “read and understand” training for all staff and during the
employee induction process employees are informed as to where all relevant
policies can be located.

Training will be provided to employees and Management at
MPL who have direct responsibility for supply chain management, particularly
with respect to the mitigation of risks within the supply chain. 

6.   Our Effectiveness in Combating Slavery
and Human Trafficking

We have reviewed existing policies
and procedures and implemented new measures this year as identified above in
order to increase our effectiveness in combatting slavery and human
trafficking.  MPL hopes that the measures currently being put into place
will further develop a robust system for identifying Modern Slavery and Human
Trafficking going forward.  We will continue to monitor and review all
processes to ensure their effectiveness.

This statement is made pursuant to
section 54(1) of the Modern Slavery Act 2015 and constitutes our Anti-Slavery
and Human Trafficking Statement for the financial year ending 31 December 2019.

Last edited on June 17, 2018

Click here to download Morningside Pharmaceuticals’ Anti Modern Slavery and Human Trafficking Statement.